CER Daily Newsfeed

Value Viewpoint: November 22, 2024

(11/22, Kimberly Westrich, LinkedIn) comments “New research from NPC in the Journal of Comparative Effectiveness Research examines the unique policy challenges associated with innovative gene therapies and puts forth a number of potential solutions to address those challenges. I, along with my colleagues Tyler Wagner, Lisabeth Buelt, and Jon Campbell, identify challenges preventing broader patient access to gene therapies, including: Challenges related to the production and distribution of gene therapy treatments; Logistical and treatment administration obstacles; and Coverage and reimbursement limitations imposed by healthcare payers.” Full

Flatiron Exec Describes Broadening Scope of Research Using Real-World Data

(11/25, David Raths, Healthcare Innovation) reports “...HCI: Does broadening out the types of research include things like looking at health equity, at how people are receiving care in lots of different types of settings? [Flatiron Health vice president of research oncology Neal Meropol, M.D.:] Exactly. The applications of our data today not only include understanding adoption of new therapies, but also understanding the real-world outcomes associated with different patterns of care, being able to perform comparative effectiveness, to understand differences in approaches that might not be amenable to doing a prospective clinical trial.” Full

'We Dodged a Bullet': Biotech and Pharma React to Selection of Marty Makary for FDA Commissioner

(11/23, Allison DeAngelis, Adam Feuerstein, Matthew Herper, Lizzy Lawrence, Nicholas St. Fleur, and Jonathan Wosen, STAT Plus) reports “...STAT reporters reached out to key figures in biotech, pharma, and medical devices to find out what they think about President-elect Trump's pick of Johns Hopkins pancreatic surgeon Martin ‘Marty’ Makary as commissioner of the [FDA]. Makary, like Trump's intended Health and Human Services selection, Robert F. Kennedy Jr., is part of the ‘Make America Healthy Again’ movement, focused on addressing chronic disease. He was also a critic of some Covid-19 pandemic measure, including vaccine mandates.” Subscription Required

Dems Call For Final March-In Rights Framework Before Trump Takes Over

(11/22, Gabrielle Wanneh, InsideHealthPolicy) reports “...‘The fact that the Biden administration had this thing for eight months, they rolled it out with the White House touting it as an important tool to lower drug prices, and then they never pulled the trigger...We heard rumors it was going to come out imminently. It never did. And I don't know the reason, but my speculation is that the Biden administration realized this thing is a loser,’ [the Bayh-Dole Coalition’s Joe Allen] told Inside Drug Pricing.” Subscription Required